RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells

Brain Research

Volumn 1521, Issue , 2013, Pages 59-67

  Chen, Ling ^a   Huang, Enping ^a   Wang, Huijun ^a   Qiu, Pingming ^a   Liu, Chao ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangzhou Forensic Science Institute   (China)

Author keywords

synuclein; Methamphetamine; Neurotoxicity; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN SHRNA; DOPAMINE TRANSPORTER; METHAMPHETAMINE; NITRIC OXIDE SYNTHASE; NITROGEN; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NERVE CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; WILD TYPE;

ALPHA-SYNUCLEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM STIMULANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKDOWN TECHNIQUES; HUMANS; METHAMPHETAMINE; NEURONS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFECTION;

EID: 84879288574     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.05.016     Document Type: Article

References (43)

1. A. Ajjimaporn, J. Swinscoe, S. Shavali, P. Govitrapong, and M. Ebadi Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells Brain Res. Bull. 67 2005 466 475
2. A. Ajjimaporn, P. Phansuwan-Pujito, M. Ebadi, and P. Govitrapong Zinc protects SK-N-SH cells from methamphetamine-induced alpha-synuclein expression Neurosci. Lett. 419 2007 59 63
3. C. Alves Da Costa, E. Paitel, B. Vincent, and F. Checler Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease J. Biol. Chem. 277 2002 50980 50984
4. D.E. Cabin, K. Shimazu, D. Murphy, N.B. Cole, W. Gottschalk, K.L. McIlwain, B. Orrison, A. Chen, C.E. Ellis, R. Paylor, B. Lu, and R.L. Nussbaum Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein J. Neurosci. 22 2002 8797 8807
5. M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln, C. Levecque, L. Larvor, J. Andrieux, M. Hulihan, N. Waucquier, L. Defebvre, P. Amouyel, M. Farrer, and A. Destee Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169
6. O. Chiba-Falek, G.J. Lopez, and R.L. Nussbaum Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients Mov. Disord. 21 2006 1703 1708
7. W. Dauer, N. Kholodilov, M. Vila, A.C. Trillat, R. Goodchild, K.E. Larsen, R. Staal, K. Tieu, Y. Schmitz, C.A. Yuan, M. Rocha, V. Jackson-Lewis, S. Hersch, D. Sulzer, S. Przedborski, R. Burke, and R. Hen Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP Proc. Natl. Acad. Sci. 99 2002 14524 14529
8. M.J. Devine, K. Gwinn, A. Singleton, and J. Hardy Parkinson's disease and alpha-synuclein expression Mov. Disord. 26 2011 2160 2168
9. J.L. Eriksen, S. Przedborski, and L. Petrucelli Gene dosage and pathogenesis of Parkinson's disease Trends Mol. Med. 11 2005 91 96
10. M. Farrer, J. Kachergus, L. Forno, S. Lincoln, D.S. Wang, M. Hulihan, D. Maraganore, K. Gwinn-Hardy, Z. Wszolek, D. Dickson, and J.W. Langston Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications Ann. Neurol. 55 2004 174 179
11. A.E. Fleckenstein, T.J. Volz, and G.R. Hanson Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications Neuropharmacology 56 2009 133 138
12. F. Fornai, P. Lenzi, M. Ferrucci, G. Lazzeri, A.B. di Poggio, G. Natale, C.L. Busceti, F. Biagioni, M. Giusiani, S. Ruggieri, and A. Paparelli Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice Brain Res. Bull. 65 2005 405 413
13. B. Halliwell Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97 2006 1634 1658
14. N.K. Irina, and L.C. Jean Methamphetamine toxicity and messengers of death Brain. Res. 60 2009 379 407
15. S. Kaewsuk, K. Sae-Ung, P. Phansuwan-Pujito, and P. Govitrapong Melatonin attenuates methamphetamine-induced reduction of tyrosine hydroxylase, synaptophysin and growth-associated protein-43 levels in the neonatal rat brain Neurochem. Int. 55 2009 397 405
16. D. Kirik, C. Rosenblad, C. Burger, C. Lundberg, T.E. Johansen, N. Muzyczka, R.J. Mandel, and A. Bjorklund Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system J. Neurosci. 22 2002 2780 2791
17. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, S. Kosel, H. Przuntek, J.T. Epplen, L. Schols, and O. Riess Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat. Genet. 18 1998 106 108
18. D. Liu, L. Jin, H. Wang, H. Zhao, C. Zhao, L. Lu, B. Wu, S. Yu, P. Chan, Y. Li, and H. Yang Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells Neurochem. Res. 7 2008 1401 1409
19. E. Masliah, E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto, A. Takeda, Y. Sagara, A. Sisk, and L. Mucke Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders Science 287 2000 1265 1269
20. C.E. Moussa, C. Wersinger, Y. Tomita, and A. Sidhu Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine Biochemistry 43 2004 5539 5550
21. E.H. Norris, B.I. Giasson, H. Ischiropoulos, and V.M. Lee Effects of oxidative and nitrative challenges on α-synuclein fibrillogenesis involve distinct mechanisms of protein modifications J. Biol. Chem. 278 2003 27230 27240
22. A.W. Oaks, and A. Sidhu Synuclein modulation of monoamine transporters FEBS Lett. 585 2011 1001 1006
23. X. Peng, R. Tehranian, P. Dietrich, L. Stefanis, and R.G. Perez Alpha-synuclein activation of proteinphosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells J. Cell. Sci. 118 2005 3523 3530
24. R.G. Perez, J.C. Waymire, E. Lin, J.J. Liu, F. Guo, and M.J. Zigmond A role for alpha-synuclein in the regulation of dopamine biosynthesis J. Neurosci. 22 2002 3090 3099
25. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, and R.L. Nussbaum Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
26. D. Pubill, C. Chipana, A. Camins, M. Pallas, J. Camarasa, and E. Escubedo Free radical production induced by methamphetamine in rat striatal synaptosomes Toxicol. Appl. Pharmacol. 204 2005 57 68
27. M.K. Sapru, J.W. Yates, S. Hogan, L.X. Jiang, J. Halter, and M.C. Bohn Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi Exp. Neurol. 198 2006 382 390
28. J.B. Schulz, and B.H. Falkenburger Neuronal pathology in Parkinson's disease Cell. Tissue. Res. 318 2004 135 147
29. S.L. Senior, N. Ninkina, R. Deacon, D. Bannerman, V.L. Buchman, S.J. Cragg, and R. Wade-Martins Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein Eur. J. Neurosci. 27 2008 947 957
30. A. Sidhua, C. Wersingera, and P. Vernierb Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease FEBS Lett. 565 2004 1 5
31. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, MR. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
32. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
33. A. Storch, Y.I. Hwang, D.A. Gearhart, J.W. Beach, E.J. Neafsey, M.A. Collins, and J. Schwarz Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake J. Neurochem. 89 2004 685 694
34. D. Sulzer, M.S. Sonders, N.W. Poulsen, and A. Galli Mechanisms of neurotransmitter release by amphetamines: a review Prog. Neurobiol. 75 2005 406 433
35. B. Thomas, and M.F. Beal Parkinson's disease Hum. Mol. Genet. 2 2007 183 194
36. T.J. Volz, G.R. Hanson, and A.E. Fleckenstein The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits J. Neurochem. 101 2007 883 888
37. J. Wang, and J.A. Angulo Methamphetamine induces striatal neurokinin-1 receptor endocytosis primarily in somatostatin/NPY/NOS interneurons and the role of dopamine receptors in mice Synapse 65 2011 300 308
38. C.W. Wu, Y.H. Ping, J.C. Yen, C.Y. Chang, S.F. Wang, C.L. Yeh, C.W. Chi, and H.C. Lee Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis Toxicol. Appl. Pharmacol. 220 2007 243 251
39. F.X. Wu, W.S. Poon, G. Lu, A. Wang, H.W. Meng, L. Feng, Z.P. Li, and S.W. Liu Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells Brain Res. 1292 2009 173 179
40. M. Yamada, T. Iwatsubo, Y. Mizuno, and H. Mochizuki Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease J. Neurochem. 91 2004 451 461
41. S. Yu, X. Zuo, Y. Li, C. Zhang, M. Zhou, Y.A. Zhang, K. Uéda, and P. Chan Inhibition of tyrosine hydroxylase expression in alpha-synuclein- transfected dopaminergic neuronal cells Neurosci. Lett. 367 2004 34 39
42. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, I. Ampuero, L. Vidal, J. Hoenicka, O. Rodriguez, B. Atares, V. Llorens, E. Gomez Tortosa, T. del Ser, D.G. Munoz, and J.G. de Yebenes The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann. Neurol. 55 2004 164 173
43. W. Zhou, J. Schaack, W.M. Zawada, and C.R. Freed Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture Brain Res. 926 2002 42 50